Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study

Centre Hospitalier Universitaire, Amiens1 site in 1 country30 target enrollmentMarch 1, 2013

ConditionsOsteoarticular Infection

Interventionsteicoplanin

Drugsteicoplanin

Overview

Phase: Phase 2
Intervention: teicoplanin
Conditions: Osteoarticular Infection
Sponsor: Centre Hospitalier Universitaire, Amiens
Enrollment: 30
Locations: 1
Primary Endpoint: measure of tolerance
Status: Completed
Last Updated: 7 months ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is a biomedical research, prospective, mono centric, tolerance study Of the administration of subcutaneous teicoplanin in the treatment of osteoarticular infections.

Registry

clinicaltrials.gov

Start Date

March 1, 2013

End Date

July 1, 2015

Last Updated

7 months ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Centre Hospitalier Universitaire, Amiens

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patient over 18 years
•Inpatient orthopedic surgery
•Achieved a bone and joint infection documented gram + (staphylococci golden coagulase-negative staphylococci, enterococci, streptococci)
•Bacteria resistant to lincosamides, quinolones and rifampicin
•Bacteria susceptible to teicoplanin (MIC ≤ 4 mg / L)
•Balanced patient teicoplanin administered intravenously (2 successive doses between 30 and 40 mg / mL)

Exclusion Criteria

•Patient not affiliated to the social security
•Pregnant and lactating women
•Known hypersensitivity to teicoplanin (rash, ...)
•Patients with a central catheter or an implantable chamber
•Patient hemodialysis
•Patient has another participant biomedical research on a drug to prevent drug interactions
•Patient minor
•Patient major protected (protection of the court, wardship, trusteeship)
•Patient admitted for emergency or incapable of consent